---

$1.83

+0.0600 ( +3.39% ) 84.3K

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-12-03	Buy	22828.00	CHRISTOPHER RICHARD
2024-08-13	Buy	1600.00	TURKEL CATHERINE C.
2024-08-01	Sale	-2567.00	Carle Vanessa
2024-07-30	Sale	-12000.00	McKechnie William Edward
2024-07-30	Sale	-12000.00	Baxter Nicholas W
2024-07-30	Sale	-12000.00	TURKEL CATHERINE C.
2024-07-30	Sale	-12000.00	REESE ALBERT L JR
2024-05-15	Sale	-2500.00	Carle Vanessa
2024-05-10	Sale	-5000.00	TURKEL CATHERINE C.
2024-05-10	Sale	-5000.00	Baxter Nicholas W

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.